ILEU17106 / ARO-021 / Jane LiesveldResearch Question:
Does the drug Crenolanib help the survival of AML patients better than the drug Midostaurin?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
A phase III randomized multi-center study designed to compare the efficacy of crenolanib
with that of midostaurin when administered following induction chemotherapy, consolidation
chemotherapy and bone marrow transplantation in newly diagnosed AML subjects with
FLT3 mutation. About 510 subjects will be randomized in a 1:1 ratio to receive either
crenolanib in addition to standard first line treatment of AML (chemotherapy and if
eligible, transplantation) (arm A) or midostaurin and standard treatment (arm B).
Potentially eligible subjects will be registered and tested for the presence of FLT3
mutation. Once the FLT3 mutation status is confirmed and additional eligibility is
established, subject will be randomized and enter into the treatment phase.
Study Reference #: ILEU 17106
Lead Researcher (Principal Investigator)
Jane Liesveld, MD
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Thank you for contacting us. People like you are helping URMC make our community and
world a healthier place. We sincerely appreciate your effort. A member of our research
team will be in touch with you.
Trial Not Found
The study you are looking for is not active at this time.
Return to Search